Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.67 |
| ▸ | PARP1 | P09874 | 3/20 | 0.63 |
| ▸ | BRD1 | O95696 | 1/20 | 0.63 |
| ▸ | BRD2 | P25440 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | TNKS | O95271 | 1/20 | 0.58 |
| ▸ | GUSB | P08236 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30434465 | 1.00 | BRD4 (0.67) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL349456 | 0.92 | BRD4 (0.65) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL378173 | 0.91 | BRD4 (0.64) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL348695 | 0.91 | BRD4 (0.67) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL347505 | 0.90 | BRD4 (0.62) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL348295 | 0.89 | BRD4 (0.70) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL121947 | 0.88 | BRD4 (0.77) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30434343 | 0.88 | BRD4 (0.77) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL377809 | 0.87 | HDAC1 (0.71) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30804212 | 0.87 | BRD4 (0.71) | BRD4HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | claimed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | claimed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | claimed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | claimed |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (US) | 2015-03-12 | — | — | US | claimed |
| US-8889698-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2014-11-18 | — | — | US | claimed |
| WO-2013186612-A1 | THE USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BET (BROMODOMAIN AND EXTRA TERMINAL DOMAIN) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-12-19 | — | — | WO | claimed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| WO-2013156869-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | WO | claimed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | claimed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | claimed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | claimed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | claimed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | claimed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | claimed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885HDAC3 467/4885HDAC4 833/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | BRD4 376/4885HDAC3 2066/4885HDAC4 3758/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | BRD4 922/4885HDAC3 1346/4885HDAC4 3008/4885 |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | BRD4 1/4885HDAC3 109/4885HDAC4 180/4885 |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 192/4885HDAC3 1622/4885HDAC4 804/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885HDAC3 467/4885HDAC4 833/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885HDAC3 467/4885HDAC4 833/4885 |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885HDAC3 467/4885HDAC4 833/4885 |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | BRD4 10/4885HDAC3 54/4885HDAC4 84/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | BRD4 693/4885HDAC3 869/4885HDAC4 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.